[
  {
    "ts": null,
    "headline": "Should Biogen’s (BIIB) Surging New Drug Sales Reshape Investors’ Expectations for Future Growth?",
    "summary": "Biogen recently reported third quarter 2025 earnings results that surpassed expectations, with revenue rising to US$2.53 billion and net income increasing to US$466.5 million compared to a year ago, fueled by strong sales from newly launched therapies such as LEQEMBI, SKYCLARYS, and ZURZUVAE. This performance helped offset declines in Biogen's established multiple sclerosis franchise and prompted renewed analyst confidence in the company’s evolving drug portfolio. We'll explore how Biogen’s...",
    "url": "https://finnhub.io/api/news?id=6caf634ff35b858f01f5375ffe5523c374d397e5efe1d8c0df229f9c4110b699",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762596649,
      "headline": "Should Biogen’s (BIIB) Surging New Drug Sales Reshape Investors’ Expectations for Future Growth?",
      "id": 137378638,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen recently reported third quarter 2025 earnings results that surpassed expectations, with revenue rising to US$2.53 billion and net income increasing to US$466.5 million compared to a year ago, fueled by strong sales from newly launched therapies such as LEQEMBI, SKYCLARYS, and ZURZUVAE. This performance helped offset declines in Biogen's established multiple sclerosis franchise and prompted renewed analyst confidence in the company’s evolving drug portfolio. We'll explore how Biogen’s...",
      "url": "https://finnhub.io/api/news?id=6caf634ff35b858f01f5375ffe5523c374d397e5efe1d8c0df229f9c4110b699"
    }
  }
]